Chai Discovery's $130M Series B and the open-source Chai-1 protein-structure model put the category back in conversation against AlphaFold 3 and Isomorphic Labs. Recursion and Tempus operate the largest phenomics and clinical-genomics datasets in the public-comparable set, while Insilico Medicine pushed its first generative-AI-designed molecule INS018_055 into Phase II for IPF. Owkin partners with hospitals on federated learning, EvolutionaryScale shipped ESM3 as a frontier protein language model, and Xaira Therapeutics launched in 2024 with one of the largest seed rounds in biotech history. Atomwise, Cradle, Latent Labs, and Iambic round out the computational-chemistry layer.
CATEGORY
Best Drug Discovery AI Tools
62 tools compared · 2026
Generative chemistry, protein language models, and AI scientists targeting the trillion-dollar pharma R&D bottleneck
62 drug discovery startups tracked, with the largest concentration in US. Total tracked funding: $12.1B.
Tracked
62
Total Raised
$12.1B
Countries
9
Active Deals
0
1 
Lila Sciences Cambridge, US $550M 2 
Recursion Salt Lake City, US $500M 3 
Paradigm Health Columbus, US $359M 4 
Treeline Biosciences Stamford, US $1.1B 5 
Lindus Health London, GB $78M 6 
Bioptimus Paris, FR $76M 7 
Edison Scientific San Francisco, US $70M 8 
Pathos AI — $467M 9 
Genesis Molecular AI Burlingame, US $280M 10 
Manas AI New York, US $24.6M 11 
Diffuse Bio San Carlos, United States — 12 
ChemLex Singapore, SG $45M
Funding by year — Drug Discovery
2019 → 2026Market overview
Key trends 2026
- Foundation-model biology arrives. Chai-1, ESM3, and AlphaFold 3 reset the structure-prediction baseline for in silico screening.
- Phase II readouts begin. Insilico's INS018_055 IPF program gives the first generative-AI-discovered drug a real clinical signal.
- Federated data beats centralized scraping. Owkin's hospital network model sidesteps the patient-data licensing wall that blocks others.
Benchmarks vs global
First AI-designed drug in Phase II
INS018_055 (Insilico)
vs zero pre-2023 ↑
Largest tracked round
$130M (Chai Series B)
vs Xaira's $1B 2024 launch ↑
Hit-rate uplift, AI-led campaigns
4-10x (Enveda claim)
vs traditional HTS baseline ↑
Top countries
By startup countStage breakdown
Latest round typeTop investors backing Drug Discovery
See all →Lux Capital
6 deals
General Catalyst
6 deals
GV (Google Ventures)
6 deals
SP
Sofinnova Partners
5 deals
AV
ARCH Venture Partners
5 deals
Khosla Ventures
5 deals
FP
Flagship Pioneering
4 deals
MC
Mubadala Capital
3 deals
F
F-Prime
3 deals
B
Bpifrance
3 deals
BL
Bpifrance Large Venture
3 deals
CI
Cathay Innovation
3 deals
FAQ
Frequently asked
Which AI drug-discovery startup has raised the most?
Among our tracked startups Chai Discovery leads at $130M Series B. Public peers Recursion and Tempus have raised more historically (Recursion $400M+ pre-IPO, Tempus IPO 2024) but trade as listed companies rather than VC-staged startups.
Has any AI-designed drug reached clinical trials?
Yes. Insilico Medicine's INS018_055 for idiopathic pulmonary fibrosis advanced into Phase II — the first molecule with both target identified and structure designed by generative AI to reach that stage. Several Recursion and Iambic candidates are in Phase I.
What does Chai-1 give researchers that AlphaFold 3 doesn't?
Chai-1 ships with weights downloadable for non-commercial research and matches AlphaFold 3 on ligand and antibody benchmarks. AlphaFold 3 is gated behind Isomorphic's web server with usage caps, which limits high-throughput in-silico screening pipelines.
Recent rounds in Drug Discovery
All rounds →| Date | Startup | Round | Amount |
|---|---|---|---|
| Jun 2026 | Apoha | Series A | $36M |
| May 2026 | Perceptic | Seed | $12M |
| May 2026 | Genesis Therapeutics | Strategic Equity Investment | $40M |
| May 2026 | Imperagen | Seed | $6.7M |
| May 2026 | Isomorphic Labs | Series B | $2.1B |
| Jan 2026 | Enjamb Labs | Seed | $500K |
| Dec 2025 | Chai Discovery | Series B | $130M |
| Dec 2025 | Paradigm Health | Series B | $78M |
All Drug Discovery startups
Page 3Tahoe Therapeutics
Tahoe Therapeutics, formerly Vevo Therapeutics, builds gigascale single-cell datasets to train
Raised
$30M
Stage
S-A
Alchemab Therapeutics
UK biotech using machine learning to mine patient-derived immune responses for protective
Raised
$32M
Stage
S-A
Ensocell
Cambridge, UK biotech that integrates single-cell and spatial genomics with AI to discover
Raised
$16.3M
Stage
Seed
Cellular Intelligence
Foundation models for human stem cells to industrialize cell therapy production
Raised
$47M
Stage
S-A
Adaptyv Bio
Cloud lab that experimentally validates AI-designed proteins in under three weeks
Raised
$8M
Stage
Seed
Imperagen
Closed-loop, AI-guided enzyme engineering for improved and production-ready enzyme designs.
Raised
$6.7M
Stage
Seed
Latent Labs
Building frontier generative AI models that capture the fundamentals of biology to make biology programmable.
Enveda
Enveda is learning from life to discover medicines 4X faster than the industry average by unlocking nature's hidden chemistry.
SandboxAQ
Transforming the world with AI and advanced computing, applying quantitative AI to solve complex challenges in various industries.
Xaira Therapeutics
Pioneering transformative artificial intelligence to discover and develop the next generation of life-changing medicines.
EvolutionaryScale
Frontier AI for the life sciences, enabling scientists to understand, imagine, and create proteins.
Iambic Therapeutics
Leveraging AI technologies to accelerate the discovery and development of optimised medicines for challenging diseases.
Atomwise
Our AI superplatform explores the vast universe of chemical space to discover novel, drug-like molecules unseen by others.
Cradle
Leverage AI to generate protein candidates and improve their properties, achieving more breakthroughs in fewer experiments.